FDA Rejects Ivonescimab Application for Advanced Lung Cancer Treatment

US regulator says trial evidence did not establish a statistically significant overall-survival benefit.

The US Food and Drug Administration declined to approve Summit Therapeutics' application for ivonescimab combined with chemotherapy for a specific group of patients with advanced EGFR-mutated non-small cell lung cancer. The main concern was the lack of statistically significant improvement in overall survival

Reported by: System Admin
•
November 16, 2026
•
5 min read
Dr. Arvind Deshmukh

MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH

Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute

Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.

FDA Rejects Ivonescimab Application for Advanced Lung Cancer Treatment
Photo: Clinical Archives / HealthGhuru EditorialVerified Creative Rights

Ivonescimab is an investigational cancer medicine being developed for the treatment of certain forms of lung cancer. It is designed to target both PD-1, an immune checkpoint protein, and VEGF, a protein involved in the formation of blood vessels that support tumour growth.

Summit Therapeutics sought US approval for ivonescimab in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-squamous non-small cell lung cancer carrying an EGFR mutation. These patients had experienced disease progression after treatment with a third-generation EGFR tyrosine kinase inhibitor.

The FDA issued a complete response letter, meaning the application could not be approved in its current form.

The HARMONi Phase III trial included 438 patients across 114 centres. The study showed that progression-free survival was longer in the ivonescimab group, at 6.8 months compared with 4.4 months in the control group.

However, overall survival was 16.8 months compared with 14.0 months, and the difference did not reach statistical significance. The regulator considered this evidence insufficient to establish the required benefit-risk profile for the proposed use.

The decision does not mean that the medicine has been permanently rejected or that it has no anti-cancer activity. It means further evidence is needed before the proposed treatment can receive US approval.

Dr. Arvind Deshmukh

Dr. Arvind Deshmukh

VERIFIED

Cardiologist & Electrophysiologist

Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.

Scientific References & Journal Citations

  1. National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
  2. Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
  3. European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.

Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.